Jeffrey Simmons Buys Shares of Elanco Animal Health Incorporated $ELAN

Key Points

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Jeffrey Simmons, PRESIDENT, CEO AND DIRECTOR at Elanco Animal Health Incorporated ($ELAN), bought 117 shares at an average price of $24.17, for a total transaction of $2,827.89. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Elanco Animal Health Incorporated Stock Up 0.7%

Shares of Elanco Animal Health Incorporated ($ELAN) traded around $24.29 on Tuesday, up 0.7% for the day.

Last price$24.29
Market cap$11.95B
Forward P/E18.69
PEG ratio4.04
Beta1.69
52-week low$17.11
52-week high$27.98
50-day MA$24.59
200-day MA$23.68
Current ratio2.05
Quick ratio0.91
Debt-to-equity0.64

Elanco Animal Health Incorporated Earnings

EPS (ttm)-$0.41
Revenue (ttm)$5.02B
Revenue growth10.20%
Net margin-3.96%
Return on equity-2.98%
Next earningsNov 5, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$31.21
High target$34
Low target$26
Analysts covering14

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

ExchangeNYSE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersIndianapolis, IN
CEOMr. Jeffrey N. Simmons
Employees9,400

Get Elanco Animal Health Incorporated alerts

New 13F filings, insider trades, and analyst moves on $ELAN, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.